Introduction
Fibroblast growth factor 23 (FGF23), a phosphaturic hormone that suppresses renal 1α-hydroxylase activity, has been implicated in the development of secondary hyperparathyroidism in chronic kidney disease (CKD) [1] , and circulating FGF23 values are often markedly elevated in patients treated with maintenance dialysis [2] . These increased levels have been associated with systemic outcomes, such as a more rapid deterioration in renal function [3, 4] , higher incidence of cardiovascular disease [5, 6] , and increased mortality in patients with all stages of CKD [4, 7] . They are also a predictor of rejection and progressive renal dysfunction in renal transplant recipients [8, 9] , making FGF23 of great interest both in the control of CKD mineral ion metabolism and as a mediator for end-organ damage.
Profound changes in mineral ion metabolism occur during the first few weeks post-transplantation, with marked declines in serum phosphorus concentrations often resulting in the need for oral phosphate supplementation in the first few postoperative months [10] . 1,25(OH) 2 Vitamin D (calcitriol) values are also decreased in the immediate post-renal transplant period, despite normal to elevated circulating parathyroid hormone (PTH) levels and low circulating phosphate concentrations, which should stimulate renal 1α-hydroxylase activity [11, 12] . Circulating FGF23 levels are markedly elevated in individuals with end-stage kidney disease (ESRD) [2, 13] , and several studies have demonstrated that values decline after successful renal transplantation [14] [15] [16] , approaching those of individuals with normal kidney function by 3-6 months post-transplantation [14] [15] [16] . Although FGF23 is both filtered by the kidneys [17] and enzymatically cleaved [18] , the relative contributions of filtration and degradation to its rapid decline post-transplantation are unknown. Furthermore, while some studies have linked FGF23 values to diminished circulating calcitriol levels and to increased renal phosphate excretion in the first months post-renal transplantation [19, 20] , this observation has not been confirmed by others [21] . FGF23 normally suppresses renal 1α-hydroxylase and stimulates 24-hydroxylase activity; whether FGF23 contributes to the decreased production or increased metabolism of calcitriol in the early transplant period remains unknown. Thus, our study was designed to assess the relative contribution of renal filtration to changing FGF23 values early post-renal transplantation and to assess the contribution of FGF23 to changes in 1,25(OH) 2 vitamin D metabolism during this timeframe.
Subjects and methods

Clinical characterization
All pediatric patients aged 8-21 years undergoing renal transplantation at the University of California Los Angeles (UCLA) from 1 August 2005 through 30 April 2007 were potential study candidates. Exclusion criteria included: post-operative follow-up at another institution, delayed graft function, and the use of active vitamin D sterols post-transplantation. Postoperative phosphate supplementation was prescribed at the treating physician's discretion. The study was approved by the UCLA Human Subject Protection Committee, and informed consent and/or assent was obtained from all parents and/or patients.
Demographic data, including patient age, gender, ethnicity, cause of renal insufficiency, and total dialysis time were obtained at baseline, and amount of phosphate supplementation was recorded daily during the initial period of hospitalization. Plasma, serum, and urine samples were obtained upon admission to the hospital for transplantation, daily during the first 5 post-operative days, and at 6 months posttransplantation. All samples other than the initial (pre-operative admission) sample were drawn between 6 and 8 a.m.. All samples were stored at −70°C, and non-routine measurements of serum, plasma, and urine biochemical parameters were performed after study completion.
Circulating levels of creatinine, calcium, phosphorus, albumin, PTH, FGF23, and 1,25(OH) 2 vitamin D were measured pre-operatively ("baseline" values), daily throughout the first 5 days of the post-operative period as well as on postoperative day 180. Circulating 25(OH) vitamin D and 24,25(OH) 2 vitamin D values were obtained at baseline and on post-operative days 5 and 180, and urinary concentrations of creatinine, phosphorus and FGF23 were measured on postoperative days 1, 3, 5, and 180. Biochemical determinations for serum creatinine, calcium, albumin, and phosphorus and for urinary creatinine and phosphorus were determined using an Olympus AU5400 (Olympus America Incorporated, Center Valley, PA). Serum calcium levels were adjusted based on serum albumin level by the formula: serum Ca=measured calcium+(0.8×(4 − serum albumin) 2 vitamin D levels (Heartland Assays, Charleston, SC) were assessed by radioimmunoassay. PTH levels were measured in plasma by a first generation assay (Immutopics, San Clemente, CA; normal range: 10-65 pg/ml) and FGF23 levels were determined in EDTA plasma and urine [13] using the 2nd generation C-terminal assay (Immutopics Characterization of post-transplant FGF23 excretion and degradation Two sets of 15 % poly-acrylamide gels were loaded with 45 μl of undiluted urine from four patients on day 0 and on days 0, 1, 3, and 5 post-transplantation for the western blot analysis. Preoperative urinary FGF23 concentrations, as determined by an enzyme-linked immunosorbent assay (ELISA), ranged from 6,650 to 77,500 RU/ml and had declined to between 12 and 24 RU/ml in the four subjects by day 5. Both sets of gels were run simultaneously and transferred to cellulose membranes. The first set of membranes were probed with goat anti-human FGF23(51-69) (Immutopics; dilution 1:1,000), while the second set of membranes were probed with FGF23(225-244) (Immutopics; dilution 1:1,000). Both sets of membranes were then simultaneously incubated with horseradish peroxidaseconjugated rabbit anti-goat secondary antibody (Sigma-Aldrich, St. Louis, MO) (dilution 1:5,000). Bands were visualized by chemiluminescence (Cell Signaling, Danvers, MA).
Statistical analysis
Data were expressed as the mean ± standard deviation or as the median and interquartile range. A restricted maximum likelihood (REML) mixed model with random intercept was used to examine the contribution of the following predictors: preoperative FGF23 (log transformed), pre-operative PTH (log transformed), pre-operative creatinine, and time since transplantation (days). The interactions of these predictors on the following outcomes were also analyzed: and post-transplant mineral metabolism, subjects were divided into two equal subgroups based on pre-operative FGF23 values above or below the median value of 759 RU/ml. SAS (ver. 9.2; SAS, Cary, NC) was used for all statistical analyses.
Results
Study subjects and baseline biochemical values
Of the 67 pediatric patients (37 males, 30 females) with an average age of 15.3±3.2 years who underwent renal transplantation during the study period, 46 fulfilled pre-operative entry criteria and agreed to participate in the study. Nine of the study subjects underwent pre-emptive renal transplantation; the rest were dialysis patients prior to transplantation. Two patients were excluded post-operatively-one due to delayed graft function and one due to the post-operative use of calcitriol. Thus, 44 (19 male, 25 female) subjects, aged 16.4±2.9 years, who had been receiving maintenance dialysis treatment for 23.0±25.6 months, completed the study. No patients in the study had an episode of acute rejection within the first 6 months. The majority of patients were Hispanic (52 %) or Caucasian (39 %); the rest (9 %) were either African American or Asian. Baseline demographic and biochemical data, along with amount of phosphate supplementation prescribed at day 5, in patients with baseline FGF23 values above the median as compared to those with values below the median are shown in Table 1 . The two groups did not differ based on gender, age, time on dialysis, the presence of residual renal function, cause of ESRD, or the amount of supplemental phosphate prescribed by postoperative day 5. Interestingly, however, all African American and Asian participants had pre-operative FGF23 values below the median value.
Immediately pre-transplantation, FGF23 and PTH levels were elevated at 759 (455, 2385) RU/ml and 213 (130, 410) pg/ml, respectively, while serum calcium levels and phosphorus levels were in the normal range (9.4±0.9 and 4.8±1.1 mg/dl, respectively). Serum calcitriol values were 19.3 (6.3, 32.5) pg/ml, 25(OH) vitamin D values were 25.2±11.1 ng/ml, and 24,25(OH) 2 vitamin D levels were 1.7 (0.3, 2.5) ng/ml at baseline. Pre-operative FGF23 levels correlated directly with serum creatinine concentrations (r=0.37, p<0.05) and inversely with both 1,25(OH) 2 A decline in circulating FGF23 concentration was apparent by post-operative day 1, and values remained below preoperative levels at all subsequent time-points (p<0.001). As expected, subjects with higher pre-operative FGF23 values had higher post-operative values (p<0.001) (Fig. 1) . Patients with higher pre-transplantation PTH values also had lower post-transplantation FGF23 values (p<0.05), independent of time and baseline FGF23 values. Pre-transplantation creatinine concentrations were unrelated to post-operative FGF23 values. The post-operative use of steroids had no effect on post-transplant circulating FGF23 levels; pretransplantation values of FGF23 were similar in patients receiving steroid-based and steroid-free immunosuppressive regimens, FGF23 values declined similarly in all subjects, and they did not differ by steroid use either during the first 5 post-operative days or at post-operative day 180.
Pre-operative serum creatinine concentrations in patients with lower pre-operative FGF23 values did not differ from those in patients with higher pre-operative FGF23 values (7.1±0.6 vs. 8.8±0.9 mg/dl, respectively). Values declined in all patients post-transplantation; however, post-operative creatinine concentrations were higher in patients with higher pre-transplantation FGF23 values. Creatinine values at postoperative day 5 in patients with lower versus higher FGF23 values averaged 1.2±0.2 and 1.9±0.3 mg/dl, respectively (p<0.001 for both groups from baseline, p<0.05 between groups). Pre-transplantation PTH values were unrelated to post-operative creatinine concentrations.
Pre-operatively, slightly over half the population had residual urine output. In these individuals, the FE FGF23 was 0.52±0.23 % (subjects with higher baseline FGF23 values, n=11) and 0.17±0.07 % (subjects with lower values, n=12) [difference was not significant (NS) between groups]. Posttransplantation, values were <5 % at all post-operative timepoints, even in patients with the highest baseline circulating FGF23 values, despite markedly elevated circulating plasma concentrations and despite a rapid post-operative decline in circulating concentrations in all individuals. This decline did not depend on pre-transplantation circulating values of FGF23, PTH, or creatinine.
Changes in calcium, PTH, phosphorus, and FE PO4 Serum calcium concentrations rose post-operatively (p<0.01), although a greater increase was observed in subjects with higher pre-operative FGF23 values (p<0.001 for FGF23 and p<0.01 for the interaction between pre-operative FGF23 and time) (Fig. 2) . Pre-operative PTH and creatinine levels were unrelated to changes in serum calcium. Post-transplantation, PTH values declined with time (p<0.05), and values were related to pre-transplantation PTH concentrations (p<0.001) but not to pre-operative FGF23 (Fig. 3) or creatinine levels. Serum phosphorus concentrations decreased over time (p<0.01) in all subjects, although a greater decrease was observed in individuals with higher baseline FGF23 levels (p<0.001 for the interaction between time and pre-operative FGF23 concentration) (Fig. 4) . No post-operative differences in serum phosphate were observed based on pre-operative PTH or creatinine levels. Similarly, post-operative renal phosphate excretion was related to both time (p<0.001) and the pre-operative FGF23 level (p<0.01) (Fig. 5) , but not to preoperative PTH or creatinine levels. 
Western blot characterization of FGF23 in urine
Urine FGF23 was present predominantly as the full-length, presumably glycosylated 32-kDa form. Much smaller quantities of 26-kDa and 17-kDa FGF23 fragments were also detected at baseline; following transplantation, the quantity of fulllength FGF23 decreased and detectable fragments rapidly disappeared from the urine (Fig. 7) . 
Discussion
The current study demonstrates that circulating FGF23 concentrations in the early transplant period are associated with changes in circulating phosphate and 1,25(OH) 2 FGF23 has been implicated as a regulator of phosphate and vitamin D metabolism in individuals with normal kidney function and as a major factor in the development of secondary hyperparathyroidism in CKD [1, 22] . FGF23 values have also previously been related to circulating 1,25(OH) 2 vitamin D values early in the post-transplantation period [19, 20] , although this finding has been variable between studies [21] . In the current study, FGF23 and vitamin D kinetics were assessed in the first 6 post-operative days and after 6 months as this latter time-point marks a time at which many aspects of mineral metabolism post-transplantation has reached equilibrium and sufficient re-growth of the renal nerves has occurred [23] . Individuals with higher FGF23 levels pre-transplantation failed to increase 1,25(OH) 2 2 vitamin D values increased with time (p<0.01), with a greater increase observed in subjects with higher baseline FGF23 concentrations (p<0.001 for the interaction between pre-operative FGF23 and time) Fig. 7 Western blot analysis of unconcentrated urine samples from 4 patients with "high" baseline FGF23 values and residual urine production pre-operatively, and on days 1, 3 and 5 after successful renal transplantation. Primary antibodies were directed against FGF23(51-69) (a) and FGF23(225-244) (b); a horseradish peroxidase-labeled secondary antibody was used for detection. The location of different protein size markers is as indicated. Urinary FGF23 concentrations, as detected by an enzyme-linked immunosorbent assay, ranged from 6,650 [patient no. 2 (P #2)] to 77,500 (P #1) RU/ml on day 0 in the 4 patients. By day 5, urinary FGF23 concentrations ranged from 12 to 24 RU/ml in the 4 subjects vitamin D during this timeframe, likely reflects improved nutritional intake post-transplantation.
Although pre-transplantation FGF23 values were unrelated to post-operative serum phosphate concentrations, patients with higher pre-operative FGF23 values demonstrated greater post-operative renal phosphate wasting. This finding suggests that circulating FGF23 values may be a better predictor of total-body phosphate burden and of post-operative phosphate wasting than is serum phosphorus itself. Indeed, 80-90 % of total body phosphate resides in bone, and bone is the major buffer for acute changes in phosphate load, such as those which occur with meals or during hemodialysis; circulating phosphate concentrations are a poor marker of total body phosphate stores [25] . Currently, at our institution, the need for phosphate supplementation is determined solely based on a serum phosphate concentration of <2.5 mg/dl. Since circulating phosphate concentrations in the first 5 days posttransplantation did not vary despite differences in circulating FGF23 values, it is not surprising that phosphate supplementation in this timeframe also did not differ between groups. Total body phosphate excretion, however, did differ markedly between groups; thus, it is likely that a difference in the need for phosphate supplementation may have manifested at a later date (i.e., weeks post-transplantation). Since calcitriol levels showed significant differences between groups, elevated pretransplant FGF23 values might help identify patients who will benefit most from calcitriol treatment post-transplantation to enhance intestinal phosphate absorption; however, calcitriol is likely to enhance FGF23 production and should thus be used with caution.
Circulating FGF23 values declined rapidly in all patients with a functioning allograft, suggesting that a difference in pre-operative kidney function may have contributed to differences in pre-operative FGF23 concentrations. However, a similar percentage of patients with pre-transplantation FGF23 values above the median value had residual renal function when compared to subjects with pre-transplantation FGF23 concentrations below the median value. Western blot analysis of urine demonstrated that prior to surgery there were large amounts of FGF23 in patients with residual urine output, most of which appeared as a 32-kDa band; this size of urinary FGF23 is indistinguishable from the intact, glycosylated FGF23 observed in the circulation of patients with ESRD [26] . Only very smaller quantities of the 17-kDa and 23-kDa FGF23 fragments were detected pre-operatively, and these disappeared rapidly from the urine posttransplantation. The antibodies used for the western blot analysis were obtained from Immutopics and are the same antibodies as those used in their FGF23 assay kits; because this technique identified predominantly intact FGF23, it is very likely that the quantity of FGF23 identified in the urine by the C-terminal FGF23 ELISA represents both the intact molecule and FGF23 fragments. However, it is important to note that the proportion of FGF23 fragments in urine was tiny as compared to the amount of the intact molecule. Whether similar quantities of fragment are detectable in the plasma post-transplantation is currently unknown. Regardless, the rapid decline in circulating FGF23, in combination with the low fractional excretion (<5 % at all time-points) suggests that declining FGF23 values post-operatively must be due in large part to degradation of FGF23, with or without suppressed FGF23 production/secretion by osteocytes, rather than due to filtration and/or secretion of the intact molecule into urine alone.
Previous data have suggested that steroid use is associated with higher FGF23 values in stable renal transplant recipients [27] . In our study, however, similar percentages (approximately one-third) of patients with baseline circulating FGF23 levels above and below the median concentration were assigned to steroid-based regimens, and no differences in FGF23 or in any other biochemical marker were observed between patients receiving steroids and those on steroid-free protocols at any time-point. Although even patients maintained on "steroid-free" immunosuppressant regimens receive a large bolus of steroids intra-operatively, which might be expected to influence FGF23 values in the first 5 days post transplantation, no differences were observed at day 180, by which time the stimulatory effect of intraoperative steroids would likely have disappeared. While this study was not specifically designed to assess the clinical effects of steroids on circulating FGF23 concentrations and although inflammation, which is suppressed by steroid therapy, was not assessed [28] , our data suggest that circulating FGF23 values may not be modified by steroid immunotherapy post-renal transplantation.
Although the current sample size is limited in its ability to detect major differences in FGF23 values based on ethnicity or on the etiology of end-stage renal disease, it is interesting to note that all African American and Asian participants had pre-operative FGF23 values that were below the median and thus consistent with findings in previous epidemiologic studies of African American patients [4, 7] . Similarly, although definitive studies linking etiology of renal disease with FGF23 values are lacking, all patients in our study with genetic causes of their renal disease had baseline FGF23 values above the median. Further studies are warranted to assess whether these data represent a true phenomenon.
FGF23 has been identified as a potential regulator of PTH levels in animal models [29, 30] ; but the results of our study do not support a role for FGF23 levels in the regulation of PTH values in the early post-transplant period. Although an inverse relationship between FGF23 and PTH values existed pre-transplantation, PTH levels declined rapidly postoperatively, and values were not related to pre-or postoperative FGF23 concentrations. Based on our results, we are unable to rule out a potential suppressive effect of FGF23 on PTH post-transplantation, however, as increasing values of 1,25(OH) 2 vitamin D in subjects with lower FGF23 values may have obscured the suppressive effect of FGF23 on PTH.
Although the study was limited by a short window of observation, a relatively small sample size, and the use of a convenience sample (with its potential for bias), the study highlights important physiological changes in mineral metabolism in the early post-transplantation period. Pre-transplant FGF23 values are significantly related to 1,25(OH) 2 vitamin D levels but not 24,25(OH) 2 vitamin D values in the early transplant period, suggesting that suppression of renal 1α-hydroxylase may play a greater role than the stimulation of 24-hydroxylase activity in FGF23-mediated post-operative calcitriol deficiency. Filtration of the intact molecule or of large fragments does not appear to be a major contributor to the rapid post-transplantation decline in circulating FGF23 levels. Although previously published data have suggested that chronically elevated levels of FGF23 may have consequences on graft function [8, 9] and on overall survival [9] , prospective studies are needed to determine whether control of FGF23 levels either pre-or post-transplantation can affect clinical outcomes.
